Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 May 8:8:305.
doi: 10.3389/fcell.2020.00305. eCollection 2020.

Breathing New Life into the Mechanisms of Platinum Resistance in Lung Adenocarcinoma

Alvaro Gonzalez-Rajal  1 , Jordan F Hastings  2 , D Neil Watkins  3   4 , David R Croucher  2   5 , Andrew Burgess  1   6
Affiliations

Breathing New Life into the Mechanisms of Platinum Resistance in Lung Adenocarcinoma

Alvaro Gonzalez-Rajal et al. Front Cell Dev Biol. .
No abstract available

Keywords: DNA damage; DNA repair; TGF-β; cell cycle; cisplatin; follistatin; p21; p53.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Overview of the recent mechanisms of resistance identified in lung adenocarcinoma. Briefly, mechanism of resistance work to increase repair of DNA damage and or prevent the triggering of cell death through inhibition of apoptotic signaling. Black solid arrows indicated activation. Red arrows indicate inhibition. Solid and dashed lines indicate direct and indirect mechanisms. Blue and orange stars indicate that loss (e.g., by RNAi, CRISPR, or chemical inhibition) confers sensitivity and resistance to cisplatin, respectively. Blue block arrow indicates potential therapeutic cisplatin synergistic treatment options. CISP, cisplatin; EMT, epithelial-mesenchymal transition; SSB/DSB, single/double strand breaks; FA, Fanconi Anemia pathway; ROS, reactive oxygen species; Cyto.C, Cytochrome C. The Figure created with BioRender.com.
See this image and copyright information in PMC

References

    1. Abbotts R., Topper M. J., Biondi C., Fontaine D., Goswami R., Stojanovic L., et al. . (2019). DNA methyltransferase inhibitors induce a BRCAness phenotype that sensitizes NSCLC to PARP inhibitor and ionizing radiation. Proc. Natl. Acad. Sci. U.S.A. 116, 22609–22618. 10.1073/pnas.1903765116 - DOI - PMC - PubMed
    1. Arbour K. C., Riely G. J. (2019). Systemic therapy for locally advanced and metastatic non-small cell lung cancer. JAMA 322, 764–774. 10.1001/jama.2019.11058 - DOI - PubMed
    1. Bray F., Ferlay J., Soerjomataram I., Siegel R. L., Torre L. A., Jemal A. (2018). Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin. 68, 394–424. 10.3322/caac.21492 - DOI - PubMed
    1. Bruno P. M., Liu Y., Park G. Y., Murai J., Koch C. E., Eisen T. J., et al. . (2017). A subset of platinum-containing chemotherapeutic agents kills cells by inducing ribosome biogenesis stress. Nat. Med. 23, 4614471. 10.1038/nm.4291 - DOI - PMC - PubMed
    1. Burgess A., Vuong J., Marzec K. A., Lichtenberg U. N., de O'Donoghue S. I., Jensen L. J. (2019). SnapShot: S-phase entry and exit. Cell 179, 802–802.e1. 10.1016/j.cell.2019.09.031 - DOI - PubMed